Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.

Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto PA, Motti ML.

Int J Oncol. 2018 Jun 27. doi: 10.3892/ijo.2018.4457. [Epub ahead of print]

PMID:
29956724
2.

Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development.

Fratangelo F, Carriero MV, Motti ML.

Front Endocrinol (Lausanne). 2018 Apr 30;9:192. doi: 10.3389/fendo.2018.00192. eCollection 2018. Review.

3.

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G, Motti ML, Carriero MV.

J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.

4.

Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.

Yousif AM, Ingangi V, Merlino F, Brancaccio D, Minopoli M, Bellavita R, Novellino E, Carriero MV, Carotenuto A, Grieco P.

Eur J Med Chem. 2018 Jan 1;143:348-360. doi: 10.1016/j.ejmech.2017.11.030. Epub 2017 Dec 1.

PMID:
29202399
5.

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

Carriero MV, Bifulco K, Ingangi V, Costantini S, Botti G, Ragone C, Minopoli M, Motti ML, Rea D, Scognamiglio G, Botti G, Arra C, Ciliberto G, Pessi A.

Sci Rep. 2017 May 2;7(1):1312. doi: 10.1038/s41598-017-01425-9.

6.

Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells.

Monti M, Iommelli F, De Rosa V, Carriero MV, Miceli R, Camerlingo R, Di Minno G, Del Vecchio S.

PLoS One. 2017 Feb 6;12(2):e0171362. doi: 10.1371/journal.pone.0171362. eCollection 2017.

7.

A Macroscopic Mathematical Model for Cell Migration Assays Using a Real-Time Cell Analysis.

Di Costanzo E, Ingangi V, Angelini C, Carfora MF, Carriero MV, Natalini R.

PLoS One. 2016 Sep 28;11(9):e0162553. doi: 10.1371/journal.pone.0162553. eCollection 2016.

8.

Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.

Genua M, Ingangi V, Fonteyne P, Piontini A, Yousif AM, Merlino F, Grieco P, Malesci A, Carriero MV, Danese S.

Inflamm Bowel Dis. 2016 Oct;22(10):2390-401. doi: 10.1097/MIB.0000000000000896.

PMID:
27537052
9.

The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.

Ingangi V, Bifulco K, Yousif AM, Ragone C, Motti ML, Rea D, Minopoli M, Botti G, Scognamiglio G, Fazioli F, Gallo M, De Chiara A, Arra C, Grieco P, Carriero MV.

Oncotarget. 2016 Aug 23;7(34):54474-54487. doi: 10.18632/oncotarget.9976.

10.

Mutant AKT1-E17K is oncogenic in lung epithelial cells.

De Marco C, Malanga D, Rinaldo N, De Vita F, Scrima M, Lovisa S, Fabris L, Carriero MV, Franco R, Rizzuto A, Baldassarre G, Viglietto G.

Oncotarget. 2015 Nov 24;6(37):39634-50. doi: 10.18632/oncotarget.4022.

11.

Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.

Yousif AM, Minopoli M, Bifulco K, Ingangi V, Di Carluccio G, Merlino F, Motti ML, Grieco P, Carriero MV.

PLoS One. 2015 May 4;10(5):e0126172. doi: 10.1371/journal.pone.0126172. eCollection 2015.

12.

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.

Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello C, Bruzzese F, Carriero MV, Budillon A.

Oncotarget. 2015 Mar 10;6(7):5324-41.

13.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z.

14.

Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.

Bifulco K, Votta G, Ingangi V, Di Carluccio G, Rea D, Losito S, Montuori N, Ragno P, Stoppelli MP, Arra C, Carriero MV.

Oncotarget. 2014 Jun 30;5(12):4154-69.

15.

UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.

Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, Di Carluccio G, De Rosa M, Pavone V.

Mol Cancer Ther. 2014 May;13(5):1092-104. doi: 10.1158/1535-7163.MCT-13-0949. Epub 2014 Apr 4.

16.

A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting.

Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, Masucci MT, De Rosa M, Pavone V, Stoppelli MP, Carriero MV.

Mol Cancer Ther. 2013 Oct;12(10):1981-93. doi: 10.1158/1535-7163.MCT-13-0077. Epub 2013 Aug 12.

17.

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.

Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F, Sessa G, Carriero MV, Normanno N, Rocco G, Pirozzi G.

Cell Death Dis. 2013 May 2;4:e620. doi: 10.1038/cddis.2013.144.

18.

Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.

Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, Masucci MT, Arra C, Pirozzi G, Stoppelli MP, Carriero MV.

PLoS One. 2012;7(9):e44806. doi: 10.1371/journal.pone.0044806. Epub 2012 Sep 25.

19.

The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.

Carriero MV, Stoppelli MP.

Curr Pharm Des. 2011;17(19):1944-61. Review.

PMID:
21711235
20.

Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors.

Carriero MV, Franco P, Votta G, Longanesi-Cattani I, Vento MT, Masucci MT, Mancini A, Caputi M, Iaccarino I, Stoppelli MP.

Curr Drug Targets. 2011 Nov;12(12):1761-71. Review.

PMID:
21707476
21.

Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.

Bifulco K, Longanesi-Cattani I, Masucci MT, De Chiara A, Fazioli F, Di Carluccio G, Pirozzi G, Gallo M, La Rocca A, Apice G, Rocco G, Carriero MV.

Sarcoma. 2011;2011:842842. doi: 10.1155/2011/842842. Epub 2010 Dec 30.

22.

The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.

Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte V, Alfano D, Pesapane A, Rossi FW, Salzano S, Rossi G, Ragno P.

Cell Mol Life Sci. 2011 Jul;68(14):2453-67. doi: 10.1007/s00018-010-0564-7. Epub 2010 Oct 24.

PMID:
20972812
23.

The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.

Bifulco K, Longanesi-Cattani I, Gala M, DI Carluccio G, Masucci MT, Pavone V, Lista L, Arra C, Stoppelli MP, Carriero MV.

J Thromb Haemost. 2010 Dec;8(12):2789-99. doi: 10.1111/j.1538-7836.2010.04075.x.

24.

Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.

Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V.

Mol Cancer Ther. 2009 Sep;8(9):2708-17. doi: 10.1158/1535-7163.MCT-09-0174. Epub 2009 Aug 25.

25.

Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells.

Baroni A, Donnarumma G, Paoletti I, Longanesi-Cattani I, Bifulco K, Tufano MA, Carriero MV.

Peptides. 2009 Feb;30(2):267-72. doi: 10.1016/j.peptides.2008.11.001. Epub 2008 Nov 12.

PMID:
19041917
26.

Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation.

Vocca I, Franco P, Alfano D, Votta G, Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski L, Stoppelli MP.

Int J Cancer. 2009 Jan 15;124(2):316-25. doi: 10.1002/ijc.23933.

27.

Cell invasiveness in sarcomas: a possibly useful clinical correlation.

Bifulco K, De Chiara A, Fazioli F, Longanesi-Cattani I, Cantelmo AR, Tirino V, Apice G, Rocco G, Lombardi ML, Carriero MV.

Tumori. 2008 Jul-Aug;94(4):505-10.

PMID:
18822686
28.

An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.

Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV.

FEBS Lett. 2008 Apr 2;582(7):1141-6. doi: 10.1016/j.febslet.2008.03.001. Epub 2008 Mar 11.

29.

In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.

Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV, Rotoli B, Rossi G, Ragno P.

Cancer Res. 2006 Nov 15;66(22):10885-90.

30.

Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.

Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP.

J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34. Epub 2006 Aug 1.

31.

The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization.

Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, Rotoli B, Rossi G, Montuori N.

Blood. 2006 Oct 1;108(7):2476-84. Epub 2006 Jun 20.

32.

Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.

Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluso G, Stoppelli MP, Carriero MV.

J Biol Chem. 2005 Jul 1;280(26):25225-32. Epub 2005 May 2.

33.

The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.

Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP.

Thromb Haemost. 2005 Feb;93(2):205-11. Review.

PMID:
15711734
34.

Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P.

Blood. 2005 Mar 1;105(5):2198-205. Epub 2004 Oct 19.

35.

Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells.

Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M, Salomon DS.

J Cell Physiol. 2004 Jan;198(1):31-9.

PMID:
14584041
36.

Early vitronectin receptor downregulation in a melanoma cell line during all-trans retinoic acid-induced apoptosis.

Baroni A, Paoletti I, Silvestri I, Buommino E, Carriero MV.

Br J Dermatol. 2003 Mar;148(3):424-33.

PMID:
12653733
37.

Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.

Silvestri I, Longanesi Cattani I, Franco P, Pirozzi G, Botti G, Stoppelli MP, Carriero MV.

Int J Cancer. 2002 Dec 20;102(6):562-71.

38.

The cleavage of the urokinase receptor regulates its multiple functions.

Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P.

J Biol Chem. 2002 Dec 6;277(49):46932-9. Epub 2002 Sep 23.

39.

Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.

Carriero MV, Franco P, Gargiulo L, Vocca I, Cito L, Fontana L, Iaccarino C, Del Pozzo G, Guardiola J, Stoppelli MP.

Biol Chem. 2002 Jan;383(1):107-13.

PMID:
11928806
40.

Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats.

Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, Perrino C, Chieffo A, Pardo F, Chiariello M.

Circulation. 2001 Jun 19;103(24):2980-6.

41.

Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.

Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 2000 Mar 15;60(6):1546-51.

42.

Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.

Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP.

Cancer Res. 1999 Oct 15;59(20):5307-14.

43.

Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.

Chiaradonna F, Fontana L, Iavarone C, Carriero MV, Scholz G, Barone MV, Stoppelli MP.

EMBO J. 1999 Jun 1;18(11):3013-23.

44.

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, Botti G, D'Aiuto G, Salvatore M.

J Clin Oncol. 1998 May;16(5):1677-83.

PMID:
9586878
45.

Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.

Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M.

J Nucl Med. 1997 Sep;38(9):1348-51.

46.

Vitronectin binding to urokinase receptor in human breast cancer.

Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, Stoppelli MP, Salvatore M.

Clin Cancer Res. 1997 Aug;3(8):1299-308.

47.

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.

Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T, Salvatore M.

Eur J Nucl Med. 1997 Feb;24(2):150-9.

PMID:
9021112
48.

Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.

Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M.

J Nucl Med. 1996 Apr;37(4):665-72.

49.

Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.

Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 1994 Oct 15;54(20):5445-54.

50.

In vitro receptor imaging for characterization of human solid tumors.

Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, et al.

Nucl Med Biol. 1994 Jul;21(5):771-4.

PMID:
9241653

Supplemental Content

Loading ...
Support Center